Surgery Alone, Surgery With Cyclophosphamide, Vinblastine, and Prednisolone (CVP), or CVP Alone in Treating Young Patients With Stage IA or Stage IIA Nodular Lymphocyte-Predominant Hodgkin Lymphoma
- DISEASE CHARACTERISTICS: - Diagnosis of nodular lymphocyte-predominant Hodgkin lymphoma - Stage IA or IIA disease PATIENT CHARACTERISTICS: - Not specified PRIOR CONCURRENT THERAPY: - No prior therapy
OBJECTIVES: Primary - Determine the 5-year event-free survival of children or adolescents with stage IA or IIA nodular lymphocyte-predominant Hodgkin lymphoma treated with surgery alone or with cyclophosphamide, vinblastine, and prednisolone. Secondary - Determine if this regimen results in a decrease in overall survival rates, in significant upstaging at relapse, or increased rates of histological transformation in these patients. OUTLINE: - Group 1 (patients with stage IA disease only): Patients undergo surgical resection of the involved lymph nodes. Patients who achieve complete resection then enter follow-up (watch and wait); patients who do not achieve complete resection enters group 2 treatment. - Group 2 (patients with stage IIA disease or incompletely resected stage IA disease): Patients receive cyclophosphamide, vinblastine, and prednisolone for 3 courses. Patients with good response enter follow-up (watch and wait). Patients without a good response are taken off protocol. After completion of study treatment, patients are followed-up periodically.
Trial Phase Phase IV
Trial Type Treatment
- Primary ID CDR0000667369
- Secondary IDs NCI-2014-02026, EURONET-PHL-LP1, EUDRACT-2007-004092-19, EU-21011
- Clinicaltrials.gov ID NCT01088750